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Treatment of Vasculitis: Beyond 
the Basics
Muhammad Ishaq Ghauri and Muhammad Shariq Mukarram
Abstract
Vasculitis is the inflammation of blood vessels in the human body. It causes 
changes and remodeling in the walls of the vessels that include thickening, narrowing 
and scarring. As a result, the blood flow to the organs and tissues gets restricted 
leading to organ damage. The cause of primary vasculitis is not known; however, 
most cases are thought to be autoimmune. In the present era, it is getting difficult 
to treat vasculitis with conventional therapies, which includes cyclophosphamide, 
methotrexate, azathioprine and mycophenolate mofetil, with increasing rates of 
relapses. Since ever, corticosteroids and cytotoxic agents or immunosuppressants 
have been the mainstay for treating systemic vasculitis. However, the introduction 
of newer biological agents have bring about a revolution in the treatment of relapses 
and in cases where there is failure to induce and sustain remission.
Keywords: vasculitis, granulomatosis with polyangiitis, ANCA-associated vasculitis, 
giant cell arteritis, Takayasu arteritis, microscopic polyangiitis, eosinophilic 
granulomatosis with polyangiitis, anti-TNF alpha, monoclonal antibody, rheumatoid 
arthritis
1. Introduction
Vasculitis is a group of heterogeneous disorders that are characterized by inflam-
mation, also sometimes necrosis of blood vessels that includes the veins, arteries 
and capillaries. Several different forms have been identified. The pathophysiology 
of vasculitis mainly involves the immune system of the body. In large vessel disease, 
particularly giant cell arteritis, it is a T cell-driven process activating the CD4 T cells 
which in turn promote the recruitment of macrophages and monocytes to the vessel 
wall causing vascular injury. This leads to release of various inflammatory mark-
ers and cytokines for example, Interleukin 1 and Interleukin 6, causing systemic 
inflammation [1]. Antineutrophil cytoplasmic antibody (ANCA)-associated vas-
culitis involves the activation of neutrophils that release inflammatory cytokines. 
They also induce formation of neutrophil extracellular traps that are necessary 
constituent of innate immunity. These neutrophil traps are injurious to small vessels 
that not only cause vascular injury but also produce antineutrophil cytoplasmic 
antibody, therefore producing a vicious cycle [2].
The aim of this chapter is to highlight the rising number of therapeutic options 
available to treat systemic vasculitis. Use of biologics has shown promising results, 
especially Rituximab and Infliximab while others remain in the pipeline. The recent 
emergence of these agents, that selectively targets the components of immune sys-
tem, have brought an insurgence in treatment of systemic vasculitis. In this chapter 
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we discuss the treatment of vasculitis beyond the prototype drugs (cyclophospha-
mide, azathioprine, mycophenolate mofetil, etc.), with biological agents.
2. Classification
American College of Rheumatology (ACR) presented the classification criteria 
for vasculitis in 1990 (Table 1). According to this criteria vasculitis was classified 
into primary and secondary types. Both these types were dependent on the size 
of vessel involved. Vasculitis affecting the large arteries include giant cell arteritis 
(GCA) and Takayasu arteritis. Medium vessel vasculitis includes polyarteritis 
nodosa (PAN) and Kawasaki disease, while small vessel vasculitis contains granu-
lomatosis with polyangiitis (GPA) formerly known as Wegener’s granulomatosis 
(WG), Churg-Strauss syndrome now known as eosinophilic granulomatosis with 
polyangiitis (EGPS), microscopic polyangiitis (MPA), Henoch Schonlein purpura 
and cryoglobulinemia. Secondary vasculitides encompass vasculitis secondary to 
rheumatoid arthritis and various infections (bacterial, viral and fungal) [3].
Infections affecting large arteries commonly include Staphylococcus, Salmonella, 
Streptococcus, coccidioidomycosis and treponema pallidum. Hepatitis B and C 
virus along with human immunodeficiency virus and Parvovirus B19 commonly 
affects medium sized vessels. Possible mechanism for infection related vasculitis 
includes (a) direct microbial invasion and (b) immune-mediated process either by 
humoral or cellular responses. Hepatitis B virus has firmly been seen with polyar-
teritis nodosa for more than 30 years. In France, the declining rate of hepatitis B 
infection has correlated with falling levels of hepatitis B-associated polyarteritis 
nodosa. There is a strong association between hepatitis C virus and mixed essential 
cryoglobulinemia. Vasculitis has been identified as a rare manifestation of human 
immunodeficiency virus. Multiple patterns have been described including polyar-
teritis nodosa, hypersensitivity vasculitis and large vessel disease [3].
Course of rheumatoid arthritis can be complicated by medium to small vessel 
vasculitis. This is common in men and linked with positive RA factor. It may present 
in a variety of ways including distal arteritis, splinter hemorrhages, peripheral 
neuropathy with mononeuritis multiplex and aortitis [4].
In year 2012 the International Chapel Hill Consensus conference adopted names 
for vasculitis on nomenclature of vasculitides as shown in Table 2. This classified 
vasculitis not only according to the size of vessel involved (as in ACR criteria) but 
also included a few other subtypes mainly, variable vessel vasculitis, single organ 
vasculitis, vasculitis associated with systemic diseases and vasculitis associated with 
probable etiology [5].
Dominant vessel Primary Secondary
Large arteries Giant cell arteritis
Takayasu arteritis
Aortitis associated with 
rheumatoid arthritis, infections
Medium arteries Classic polyarteritis nodosa
Kawasaki disease
Hepatitis B-associated, 
polyarteritis nodosa
Small vessels and 
medium arteries
Granulomatosis with polyangiitis, Churg-
Strauss syndrome, microscopic polyangiitis
Vasculitis secondary to 
rheumatoid arthritis, drugs
Small vessels Henoch-Schonlein purpura
Cryoglobulinemia
Drugs, hepatitis C associated, 
infections
Table 1. 
ACR classification of vasculitis [3].
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A wide range of drugs have been reported to cause a vasculitic reaction. 
ANCA-associated vasculitis has been attributed to use of various drugs including 
Hydralazine, Propylthiouracil, Allopurinol and Sulfasalazine. Leukotriene recep-
tor antagonist, Montelukast and Zafirlukast, have been linked to Churg-Strauss 
syndrome. Acute vasculitis may be the presenting feature of an undiagnosed 
malignancy. Common malignancies associated with vasculitis are myelodysplasia, 
lymphoma and multiple myeloma [3].
3. Treatment with biological agents
3.1 Rituximab
It is a monoclonal antibody, which is directed against CD20 that is expressed 
on developing B cell. Although not clearly understood, this antibody can induce 
apoptosis of these developing B cells. In April 2011, Rituximab was the first agent to 
be approved by FDA for the treatment of vasculitis [6].
Large vessel vasculitis
Takayasu’s arteritis
Giant cell arteritis
Medium vessel vasculitis
Polyarteritis nodosa
Kawasaki disease
Small vessel vasculitis
Anti-neutrophil cytoplasmic antibody-associated vasculitis
Microscopic polyangiitis
Granulomatosis with polyangiitis
Eosinophilic granulomatosis with polyangiitis
Immune complex small vessel vasculitis
Cryoglobulinemic vasculitis
IgA vasculitis (Henoch Schonlein purpura)
Variable vessel vasculitis
Behcet’s disease
Vasculitis associated with systemic disease
Lupus vasculitis
Rheumatoid vasculitis
Sarcoid vasculitis
Vasculitis associated with probable etiology
Hepatitis C-associated cryoglobulinemic vasculitis
Hepatitis B-associated vasculitis
Drug-associated immune complex vasculitis
Drug-associated ANCA-associated vasculitis
Table 2. 
Modern Chapel Hill classification [5].
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In the Rituximab in ANCA-associated vasculitis (RAVE) trial, patients with 
GPA and MPA who were being given steroid therapy were randomized and received 
either oral cyclophosphamide or I/V Rituximab (four infusions). Patients who were 
given cyclophosphamide were switched to azathioprine after going into remission 
while those with Rituximab were switched to oral placebo. At the end of 6 months, 
Rituximab was found to be non-inferior to cyclophosphamide at inducing remis-
sion and was found to be superior to cyclophosphamide for patients with relapsing 
disease [6].
Another study showed single course of Rituximab to be non-inferior to 
oral cyclophosphamide, which was followed by azathioprine for remission 
 maintenance [7].
In the Rituximab versus cyclophosphamide in ANCA-associated vasculitis 
(RITUXVAS) trial, where 44 patients were diagnosed with ANCA-associated 
vasculitis, patients were randomized to receive Rituximab along with only two infu-
sions of cyclophosphamide. This was compared with patients who were given I/V 
cyclophosphamide for 3–6 months followed by azathioprine. The rate of sustained 
remission was similar in both groups [8].
These studies indicate that Rituximab is comparable in efficacy to cyclophos-
phamide for remission induction. Moreover, Maintenance of remission under 
Rituximab in systemic ANCA-associated vasculitis (MAINRITSAN) trial 115 
patients with either GPA or MPA were given either azathioprine or Rituximab in a 
dose of 500 mg IV × 2 doses (after achieving remission with cyclophosphamide). 
At the end of the study, major relapse rate was significantly lower in patients who 
received Rituximab [9].
Rituximab has also shown remarkable results in patients with EGPA whose dis-
ease was refractory to usual treatments (e.g. cyclophosphamide). One of the largest 
case series showed nine patients with EGPA refractory to conventional therapy, 
when treated with Rituximab were either in total or partial remission at the end of 
3 months [10].
The safety and efficacy of Rituximab has been evaluated by Puechal et al. in 
patients with active systemic rheumatoid vasculitis (SRV). Out of 17 patients with 
active SRV who were treated with Rituximab, 12 patients achieved complete remis-
sion of their disease at the end of 6 months. The Birmingham Vasculitis Activity 
Score (BVAS) for rheumatoid arthritis dropped down from a baseline of 9.6 to 0.6 
and the daily average dose of Prednisolone declined from 19.2 to 9.7 mg. After a 
year, 14 patients were in sustained remission [11].
Rituximab works by acting over B cells, clearing them from the body. It is the 
most extensively studied agent that has proved to be efficacious in most forms of 
vasculitis, especially ANCA-associated vasculitis. It is now the preferred choice over 
cyclophosphamide in order to reduce the adverse effect profile. Also, Rituximab 
is considered a suitable therapeutic option for inducing remission in patients with 
active vasculitis associated with rheumatoid arthritis.
Table 3 summarizes the clinical outcomes of different trials carried out using 
Rituximab as treatment for systemic vasculitis.
3.2 Infliximab
This is an IgG1, kappa monoclonal antibody specific for human tumor necro-
sis factor alpha. TNF alpha possesses multiple pro inflammatory properties for 
example, induction of Interleukin 1 and Interleukin 6, neutrophil activation etc. 
According to recent research, Infliximab is in phase 3 clinical development for treat-
ment of Kawasaki disease [12].
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One clinical trial studied the role of Infliximab in granulomatosis with poly-
angiitis exclusively. These patients were followed even after the discontinuation 
of Infliximab to monitor the remission maintenance. The reduction of their 
Birmingham Vasculitis Activity Score was significant. Surprisingly no severe 
adverse effects, deaths or infections were noted [13].
Use of TNF alpha inhibitors is not encouraged in giant cell arteritis. In a random-
ized controlled trial, some newly diagnosed patients with giant cell arteritis were 
given Infliximab along with corticosteroids (before tapering them). No significant 
difference was observed in patients who were successfully tapered off corticosteroids. 
Moreover, few subjects had a higher infection rate with the use of Infliximab [14].
Use of Infliximab has shown great effectiveness in refractory Kawasaki disease 
[15]. Single-dose Infliximab (5 mg/kg) was given to seven patients who failed to 
achieve remission with the standard therapy. These patients showed improvement 
without any adverse effects [16]. In another study, good response was seen in two 
patients with Kawasaki disease when treated with Infliximab who had a relapse 
with the conventional therapy [17].
This anti-TNF (tumor necrosis factor) agent has shown promising results in 
Wegener’s granulomatosis in reducing the disease as well as inducing remission. Use 
of Infliximab is encouraged in medium vessel vasculitis. Patients with Kawasaki 
disease, who failed to respond to conventional therapy and those who experienced 
a relapse, reacted well to this agent. Unfortunately its use in giant cell arteritis 
is not promoted as suggested by a clinical study (as discussed above) in which 
patients with giant cell arteritis were treated with Infliximab showed no significant 
response, instead resulted in a higher rate of infection.
Table 4 summarizes the clinical outcomes of different studies and trials showing 
effectiveness of Infliximab in different types of vasculitis.
Study Agent Disease Outcome
RAVE trial Rituximab GPA and MPA Rituximab was found to be non-inferior to 
cyclophosphamide at inducing remission and 
superior to cyclophosphamide for patients with 
relapsing disease
RITUXVAS trial Rituximab ANCA-
associated 
vasculitis
Rate of sustained remission were similar in 
patients taking Rituximab vs. those given 
cyclophosphamide alone
MAINRTSAN 
trial
Rituximab GPA/MPA Significantly reduced the relapse rate
Table 3. 
Rituximab trials [6, 8, 9].
Study Agent Disease Outcome
Lamprecht et al. Infliximab WG Decrease in BVAS. No deaths, infections or 
adverse effects
Randomized trial Infliximab GCA No significant difference. Increased rate of 
infection
Burns et al. Infliximab KD Improvement in patients who failed to achieve 
remission by standard therapy/refractory disease
Table 4. 
Infliximab trials [13–15].
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3.3 Etanercept
This is one of the most rigorously studied agent, which is also a tumor necrosis 
factor inhibitor. Its role has been studied in GPA and MPA for maintenance of 
remission. In WGET, 174 patients received methotrexate or cyclophosphamide 
for their remission and were then randomized to get Etanercept or placebo. 
Unfortunately, there was no significant difference in rate of sustained remission 
between Etanercept and placebo [18].
Etanercept (25 mg twice weekly) was given to 20 patients with Wegener’s granu-
lomatosis over a period of 6 months, in twice-daily dose. Out of these patients, 
70% had never had remission of their disease. This drug was combined with either 
cyclophosphamide or methotrexate. During the treatment, 80% patients went into 
disease remission and their Birmingham Vasculitis Activity Score fell significantly. 
However, three patients experienced major flare despite the therapy [19, 20].
The major drawback is the increased incidence of cancer in patients treated 
with Etanercept. Six of 92 patients developed a solid tumor. These tumors included 
mucinous adenocarcinoma of colon, metastatic cholangiocarcinoma, renal cell 
carcinoma and breast carcinoma [21].
Wegener’s granulomatosis itself is also associated with increased risk of malig-
nancy. The specific malignancies associated with it are bladder carcinoma, squa-
mous cell carcinoma, leukemia and lymphomas [22].
Use of these two agents (Infliximab and Etanercept) have shown promising results 
in Takayasu arteritis as demonstrated by a case series in which 15 patients with treat-
ment resistant disease were treated with either of the drug. After introduction of these 
agents, the average dose of corticosteroid dropped from 20 mg (range 12.5–40 mg) to 
0 mg (range 0–20 mg). Among these 15 patients 93% showed remarkable improve-
ment and 67% experienced steroid free remission for up to 3 years [23].
Etanercept is one of the most widely studied agents, which is also an anti-TNF 
drug, and has been seen to be beneficial not only in ANCA-associated vasculitis but 
also in large vessel vasculitis (Takayasu arteritis). The biggest disadvantage of this 
medication is the higher incidence of different types of cancers.
Table 5 summarizes two trials showing clinical outcomes of Etanercept in patients 
with Wegener’s granulomatosis also known as granulomatosis with polyangiitis.
3.4 Belimumab
This is a human IgG1 gamma monoclonal antibody specific for soluble human B 
lymphocyte stimulator protein, also known as B cell-activating factor. Surprisingly, 
this is the only drug in late stage development for microscopic polyangiitis [12].
Currently this agent is in Phase 3 trial. Its efficacy and safety are being tested in 
a randomized, double blind study in combination with azathioprine. The dose given 
to patients is 10 mg/kg at days 0, 14, and 28 then after every 28 days till the study 
ends (clinical trials) [24].
Study Agent Disease Outcome
WGET trial Etanercept WG No significant difference in rate of sustained remission 
between Etanercept and placebo
Luqmani et al. 
and Stone et al.
Etanercept WG 80% patients went into disease remission and their BVAS 
fell significantly. Three patients developed major flare
Table 5. 
Etanercept trials [18–20].
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Belimumab is a relatively newer agent that is currently under trial but has shown 
positive results in treatment of microscopic polyangiitis.
3.5 Mepolizumab
Mepolizumab is an Interleukin 5 humanized monoclonal antibody that binds 
to free Interleukin 5. It causes arrest of bone marrow eosinophil maturation. This 
monoclonal antibody is directed against Interleukin 5, which is a cytokine critical 
for activation of eosinophils. Mepolizumab when administered in a dose of 300 mg 
subcutaneously every 4 weeks, proved to be effective in prolonging disease remis-
sion, reducing the use of steroid [25].
Use of this agent has shown prompt normalization of peripheral eosinophil 
counts, as well as reduction in glucocorticoid usage. Two studies that showed use of 
Mepolizumab in EGPA, it led to decreased disease activity, normalization of eosino-
phil count and reduction of steroid use. However, cessation of this drug resulted in 
disease flare [26, 27].
Mepolizumab works by halting activation of eosinophils, acting directly on 
them. This biological agent is recommended in treating Churg-Strauss syndrome, 
although it is still under various trials. The major drawback is the disease flare 
caused after discontinuing the medication.
3.6 Tocilizumab
Tocilizumab is a humanized monoclonal antibody that binds to membrane-
bound and soluble Interleukin 6 receptors and inhibits Interleukin 6 signaling 
pathways [28].
A study assessed eight patients who had refractory Takayasu arteritis. Two cases 
were refractory to Infliximab and three did not reach remission on steroids and 
methotrexate. Altogether eight patients received Tocilizumab and were followed 
for 18 months. Of these eight patients, seven achieved remission. This shows that 
Tocilizumab can be a potential therapy for patients with Takayasu arteritis refrac-
tory to anti-TNF alpha therapy [29].
A retrospective study assessed the effectiveness of Tocilizumab in complicated 
large vessel vasculitis. Patients were treated with Tocilizumab out of which eight 
had giant cell arteritis, two had large vessel vasculitis associated with rheuma-
toid arthritis and one had Takayasu arteritis. These patients were followed for 
23 months. At the end of duration, seven patients were in remission, one patient 
relapsed after discontinuing the drug, and one patient suffered from serious 
infective complication. Two patients died, although cause of death was not 
attributable to the use of Tocilizumab. Three relapses occurred but remission was 
regained by switching the usual subcutaneous administration of Tocilizumab to 
 intravenous [30].
Glucocorticoids are the conventional treatment for giant cell arteritis but adverse 
effects are common, so are the relapses, soon after tapering the steroids. Although 
the exact cause of death is not known, cytokines such as tumor necrosis factor alpha 
and Interleukin 6 have been implicated. A retrospective study included 134 patients 
from 40 different centers who were diagnosed with giant cell arteritis either by tem-
poral artery biopsy or imaging techniques. All these patients had received high dose 
of steroids in past and majority of patients had been given biologic immunosup-
pressives such as Abatacept, Infliximab or Rituximab. Tocilizumab was given either 
intravenously (8 mg/kg 4 weeks apart) or subcutaneously (162 mg/week). At the 
end of 1 month the ESR and CRP had fallen and percentage of patients with anemia 
had decreased. Those who were followed for 2 years, amongst them 39 were seen 
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in remission with acute phase reactants within normal limits and minimum steroid 
dose (0–5 mg/day). However, after an average follow up of 12 months, 32 patients 
reported an adverse infection because of which 17 patients had to discontinue the 
therapy [31].
Tocilizumab works against the pro-inflammatory cytokine Interleukin 6 and 
has proven its efficacy in Takayasu arteritis that has failed to respond to Infliximab. 
Giant cell arteritis, non responsive to various other biological agents, has reacted 
remarkably to Tocilizumab by achieving disease remission in most of the cases. 
Despite all its applauding outcomes, life-threatening infection remains a serious 
complication.
Table 6 shows outcomes of studies that have evaluated the effectiveness of 
Tocilizumab in different types of vasculitis.
Table 7 summarizes the commonly used agents to treat systemic vasculitis, as 
discussed in this chapter, along with its mechanism of action and dosages.
4. Conclusion
In recent times use of high dose corticosteroids, cytotoxic and immunosuppres-
sant drugs has improved the prognosis of systemic vasculitis dramatically. However, 
some patients still do not respond to conventional therapy or may not achieve 
remission. Few of them would relapse and a large number of patients develop illness 
secondary to the adverse effects caused by long term use of these drugs. The advent 
Agent Mechanism of action Dosage
Rituximab Monoclonal antibody directed against CD20 500 mg intravenous
Infliximab Anti-TNF alpha 5 mg/kg intravenous
Etanercept Anti-TNF alpha 25 mg intravenous
Belimumab Monoclonal antibody that inhibits B cell 
activating factor
10 mg/kg intravenous
Mepolizumab Monoclonal antibody directed against 
Interleukin 5
300 mg subcutaneous
Tocilizumab Monoclonal antibody directed against 
Interleukin 6
8 mg/kg intravenous 162 mg 
subcutaneous
Table 7. 
Commonly used biological agents in the treatment of systemic vasculitis.
Study Agent Disease Outcome
Mejla et al. Tocilizumab TA Seven out of eight cases refractory to 
either Infliximab or methotrexate achieved 
remission
Toc in large vessel 
vasculitis (Marc 
Schmalzing)
Tocilizumab GCA, RA 
vasculitis, TA
After follow up of 23 months, seven were 
in remission, one relapse after stopping the 
drug, three relapses but regained remission
IL-6 blocker exceeds 
(Nancy Walsh)
Tocilizumab GCA Patients who were on follow up till 2 years, 
out of them 39 were seen in remission. These 
patients had already taken biologics including 
Abatacept, Infliximab and Rituximab
Table 6. 
Tocilizumab trials [29–31].
9Treatment of Vasculitis: Beyond the Basics
DOI: http://dx.doi.org/10.5772/intechopen.92729
Author details
Muhammad Ishaq Ghauri and Muhammad Shariq Mukarram*
Department of Medicine, Jinnah Medical College Hospital, Karachi, Pakistan
*Address all correspondence to: shariq.msm@gmail.com
of biological agents has not just let to a better understanding of pathophysiology 
of systemic vasculitis, but has also proved to be safe and efficacious. Among these 
agents, anti-TNF and anti-B cell therapy have been the first choice in many cases. 
Although clinical data are still insufficient, these agents seem to occupy most of the 
market in near future [32].
5. Methods used for research of articles
We collected information by systematic review of the PubMed, scientific 
abstracts and by searching textbooks of Rheumatology.
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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